To improve lives by providing clarity and accessibility in diagnostic testing to better inform healthcare decisions and outcomes.
At Sunbird Bio, we’re exploring new frontiers in molecular diagnostics.
Our diagnostic platforms will provide opportunities for faster, more accurate, and more affordable results.
The enVision Platform
A Novel Assay Technology
EnVision is a versatile platform with the potential to be programmed for detection of a wide range of diseases. Its novel assay technology may help solve many of the challenges associated with traditional diagnostic methods and procedures.
Infectious Disease Testing
We are currently validating the enVision platform for infectious disease detection. Overcoming challenges of PCR testing, including the time required for DNA amplification and its dependence on the reagent supply chain.
In oncology, early diagnosis drives better outcomes. Our ability to detect cancer biomarkers can provide physicians and patients with better treatment options.
For more information about the EnVision platform see:
Ho NRY, Lim GS, Sundah NR, Lim D, Loh TP, Shao H. Visual and modular detection of pathogen nucleic acids with enzyme–DNA molecular complexes. Nature Communications. 2018;9(1):3238.
The APEX Platform
A Novel Detector of Neurodegenerative Disease
APEX is designed to detect protein aggregates that are associated with several neurodegenerative diseases. Early detection of neurodegenerative diseases can improve the success of treatments, decrease costs1, and improve a patient’s quality of life. APEX provides both patients and practitioners with a convenient blood test to diagnose and monitor neurodegenerative diseases.
For more information about the APEX platform see:
Lim CZJ, Zhang Y, Shao H, et al. Subtyping of circulating exosome-bound amyloid β reflects brain plaque deposition. Nature Communications. 2019;10(1):1144.
Our Company Founder,
Dr. Huilin Shao is a Presidential Young Professor in the Department of Biomedical Engineering and a Principal Investigator of the Institute for Health Innovation & Technology (iHealthtech) at the National University of Singapore. Dr. Shao received her BA from Cornell University, with a double major in Biological Sciences and in Physics. She completed her dual PhD (Biophysics) at Harvard University and PhD (Medical Engineering and Medical Physics) from Harvard-MIT Health Sciences and Technology (HST).
Her research is focused on developing integrated nanotechnology-based platforms for molecular analyses of novel biomarkers. She has pioneered multiple platform technologies to advance molecular diagnostics. These novel technologies have the potential to not only transform clinical practice, but also empower true patient care. Her work has been published in top journals such as Nature Biotechnology, Nature Medicine, Nature Biomedical Engineering, Nature Communications and highlighted in major reviews and popular news media (e.g., BBC and CNA). In recognition of her achievement, Dr. Shao has received multiple awards, including James Mills Pierce Award, A*STAR Independent Fellowship, NUS Early Career Research Award, the L’Oreal For Women in Science National Fellowship, the 2019 Singapore Presidential Young Scientist Award and the 2020 Springer-Nature MINE Young Scientist Award.
Our Leadership Team
Business Unit Leader: APEX, enVision
Chief Engineering Officer
Dr. Nicholas Ho
Technology Head: enVision
Technology Head: APEX
In the News
iHealthtech researchers working on Wuhan novel coronavirus (2019-nCoV) detection kit
BBC News interview with founder, Huilin Shao
New blood test could potentially diagnose Alzheimer’s even before symptoms appear
1. Meade, R.M., Fairlie, D.P. & Mason, J.M. Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles. Mol Neurodegeneration. 2019;14(29):1-14. https://doi.org/10.1186/s13024-019-0329-1.